Abstract
Binding sites for the ETS domain family of transcription factors are found in the promoters of the matrix metalloproteinase (MMP) family of matrix degrading enzymes. Evidence is accumulating that both these groups of molecules are important in the process of angiogenesis in addition to matrix degradation. Furthermore, they are both expressed in tumor tissue as well as in the normal surrounding stroma. These factors along with various sites at which they may be regulated collectively makes them attractive targets to consider for therapeutic intervention in the processes of invasion and metastasis.
Current Drug Targets
Title: ETS Proteins and MMPs: Partners in Invasion and Metastasis
Volume: 3 Issue: 5
Author(s): Sadmeet Singh, Jane Barrett, Kenji Sakata, Richard G. Tozer and Gurmit Singh
Affiliation:
Abstract: Binding sites for the ETS domain family of transcription factors are found in the promoters of the matrix metalloproteinase (MMP) family of matrix degrading enzymes. Evidence is accumulating that both these groups of molecules are important in the process of angiogenesis in addition to matrix degradation. Furthermore, they are both expressed in tumor tissue as well as in the normal surrounding stroma. These factors along with various sites at which they may be regulated collectively makes them attractive targets to consider for therapeutic intervention in the processes of invasion and metastasis.
Export Options
About this article
Cite this article as:
Sadmeet Singh , Jane Barrett , Kenji Sakata , Richard G. Tozer and Gurmit Singh , ETS Proteins and MMPs: Partners in Invasion and Metastasis, Current Drug Targets 2002; 3 (5) . https://dx.doi.org/10.2174/1389450023347489
DOI https://dx.doi.org/10.2174/1389450023347489 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Urokinase Receptor Interactome
Current Pharmaceutical Design Actions of the Anti-Angiogenic Compound Angiostatin in an Animal Model of Alzheimer’s Disease
Current Alzheimer Research Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Stem Cells in Brain Tumorigenesis and their Impact on Therapy
Current Stem Cell Research & Therapy Modulation of Poly(A)-specific Ribonuclease (PARN): Current Knowledge and Perspectives
Current Medicinal Chemistry IAPs, their Antagonists and their Role in Neurological Disease and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Urokinase Receptor and Integrin Interactions
Current Pharmaceutical Design The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
Current Cancer Drug Targets Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice
Current Cancer Drug Targets MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Meet Our Associate Editorial Board Member
Current Drug Delivery Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors
Current Drug Targets Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design